Trump Administration Ends Medicaid and CHIP Reimbursement for Sex-Change Procedures for Minors, Report Says

President Donald Trump’s administration has ended Medicaid and Children’s Health Insurance Program, or CHIP, reimbursement for sex-change procedures for minors, according to a report published Tuesday by Zero Hedge that cites a statement attributed to the Trump administration and circulated through American Greatness.

The report says the change is designed to stop federal taxpayer dollars from paying for gender transition-related procedures for children and to address clinical concerns, including officials’ view that the risks can be potentially irreversible and that there is not enough evidence demonstrating a sufficient clinical benefit for minors.

The administration action, as described in the report, would apply to both Medicaid and CHIP, two major health coverage programs jointly administered by federal and state authorities. The coverage decision affects how states structure provider payments and medical authorization pathways for eligible enrollees, given that federal matching funds are tied to covered services under the programs.

In addition to the reimbursement decision, the report characterizes the administration’s rationale as a policy shift aimed at reducing federal financial support for procedures that it says lack adequate supporting evidence. It also frames the approach as an effort to limit coverage of treatments officials associate with potentially long-lasting effects.

The report does not provide, in the available summary, specific implementation details such as the effective date, whether the change will be delivered through program guidance, rulemaking, or a contract or coverage letter, or how states will be instructed to modify prior authorizations or billing practices for existing requests. It also does not identify which exact procedures the administration’s action covers beyond “sex-change procedures” for minors.

Opponents of Medicaid and CHIP restrictions on gender transition-related care have historically argued that such limits interfere with medical decision-making for children and can raise administrative and legal questions, while supporters of Medicaid restrictions often argue that the federal government should limit coverage of controversial or insufficiently supported treatments. The Zero Hedge report, however, does not include primary text of the administration’s order or guidance in the available packet, so those broader disputes are not independently resolved here.

If the announcement proceeds as described, the immediate practical impact would be felt in the Medicaid and CHIP claims systems used by states, by clinicians billing for services that would no longer be covered, and by beneficiaries and families who previously relied on federal reimbursement for particular treatments. For affected families, the policy shift would likely require medical providers to seek alternative coverage pathways or to rely on other forms of care, but the precise transition process is not described in the report summary.